HRMY — Harmony Biosciences Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapSuper Stock

Annual income statement for Harmony Biosciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	160	305	438	582	715
Cost of Revenue
Gross Profit	132	250	354	461	558
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	165	244	318	400	524
Operating Profit	-5.65	61.4	120	182	191
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-36.9	37.4	105	173	192
Provision for Income Taxes
Net Income After Taxes	-36.9	34.6	181	129	145
Net Income Before Extraordinary Items
Net Income	-36.9	34.6	181	129	145
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-63.8	34.6	181	129	145
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.724	0.993	2.97	2.25	2.51